Navigation Links
Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
Date:12/27/2007

First Patients Enrolled and Being Treated

BETHESDA, Md., Dec. 27 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO) (AIM: NWBT; NWBS) ("NWBT") today announced that a Phase I/II clinical trial in at least 30 patients, using DCVax(R)-L for recurrent ovarian cancer, has begun at The University of Pennsylvania Center for Research on Early Detection and Cure of Ovarian Cancer and the Abramson Cancer Center. The first patients have been enrolled and have undergone initial treatment steps in preparation for receiving DCVax(R)-L. The trial involves two sequential studies, and comprises an innovative combination of multiple treatment modalities. DCVax(R)-L forms the cornerstone of the treatment regimen, and is complemented by administration of low doses of certain existing approved drugs to help improve the immune system environment, as well as by adoptive transfer of patients' DCVax(R)-L primed T cells. The principal investigators for the trial are Dr. George Coukos and Dr. Sarah Kim, and the Penn Investigational New Drug ("IND") sponsor is Dr. Carl June. The funding is being provided by the Ovarian Cancer Vaccine Initiative. (See below for more information about this Initiative.)

DCVax(R)-L is a personalized immunotherapy for cancer, which is made from a patient's own dendritic cells (the master cells which initiate and manage the overall immune system response to a disease), and the "antigens" (biomarkers) from the patient's own tumor tissue which has been surgically removed as part of the standard of care. Such immunotherapy is sometimes referred to as a "therapeutic vaccine," as it is designed not to prevent cancer but to treat patients who already have cancer.

In the first study being conducted by NWBT and Penn, patients will first undergo standard surgery to reduce their tumor burden. Patients will then receive limited doses of two existing drugs to improve the immune system environment and mod
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
2. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
3. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
4. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Novel Technology Breaks Through Cancer Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , August 28, 2015 The ... in collaboration with one of the leading academics in the ... (current world record holder in life extension for model animals ... into biology of aging and age-related diseases, primarily, around the ... work has just been published as "Stability analysis of a ...
(Date:8/28/2015)... LOS ANGELES , FARUM, Denmark ... -- On July 31, 2015 the US Food ... for the treatment of Major Depressive Disorder in adult patients ... medication in the current episode. TMS is a non-invasive technique ... implicated in patients suffering from Major Depressive Disorder. The procedure ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 ... anunció hoy su participación en el  Congreso de ... soluciones cardiológicas más recientes y novedosas, entre ellas ... conectan a las personas y la tecnología con ... a diagnosticar, guiar los tratamientos y permitir atención ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... Oct. 5 Osseon Therapeutics, Inc. announced its ... North American Spine Society,s (NASS) annual meeting in ... facilitate treatment of vertebral compression fractures (VCFs) that ... fibrotic metastases.  The Osseoflex DR Steerable Bone Drill ...
... SUNNYVALE, Calif., Oct. 5 Accuray Incorporated (Nasdaq: ... of radiosurgery, announced today that the company was awarded a ... U.S. Government to be used toward further development of a ... grant will fund the development of a next generation, compact ...
Cached Medicine Technology:Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill 2Accuray Awarded $1 Million Grant by U.S. Government 2Accuray Awarded $1 Million Grant by U.S. Government 3
(Date:8/30/2015)... ... 2015 , ... Scientists in France say asbestos exposure may put workers at ... Mesothelioma has just posted an article on the new research. Click here to ... incidence among 2,024 French asbestos plant workers from 1978 to 2009. In addition to ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Kathleen Kall has been promoted from Administrative assistant to Executive Assistant ... communication, you’ll interact with a proven professional, focused on your goals. Kathleen ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , The ... PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale Avene ... , “Before, a threshold of $49.00 was required to qualify for free standard shipping,” ... free standard shipping for customers regardless of the item’s selling price.” , With competitive ...
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of ... an entire short segment to the subject of diabetes. Diabetes is a debilitating health ... basis, but recent advancements in medical science may prove to be a significant breakthrough ...
Breaking Medicine News(10 mins):Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... a small molecule that can turn the survival signal for ... molecule mimics the activity of Smac, a protein that triggers ... researchers say their findings suggest that Smac-mimetic compounds could be ... Such therapy may be less toxic to healthy cells than ...
... Zero In on Rac1, Rac2 Genes as ... Molecular Targets, ... of Cancer Cell, researchers at Cincinnati Children,s Hospital Medical,Center reported that they ... spread of chronic myelogenous leukemia,(CML) in mice. When these genes, Rac1 ...
... 12 The American Cancer Society,is looking for individuals ... personal interest in the battle against cancer to serve ... be funded by the,organization,s research and training grants. These ... such as having had a,family member with cancer, having ...
... Stock Exchange Symbol: AKL, MONTREAL, Nov. 12 ... development company focused on developing therapies for the,inhalation ... from,its pilot GHRH Phase II study. Within only ... significant stimulation of endogenous growth hormone (GH),secretion and ...
... International,Isotopes Inc. (OTC Bulletin Board: INIS) announces ... ending September 30, 2007. REVENUE: Revenue for ... was $1,486,112 and $3,592,049 respectively, as compared to,$1,458,260 ... These numbers,represent an increase of 2% for the ...
... Nov. 12 HLM Venture Partners announced today,that it ... financing of,CaseNET, Inc. CaseNET, based in Waltham, MA, is ... enterprises and government,agencies a software solution for medical and ... $4 million to the round and was joined,by existing ...
Cached Medicine News:Health News:Smac-ing lung cancer to death 2Health News:Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Leukemia 2Health News:Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Leukemia 3Health News:American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 2Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 2Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 3Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 4Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 5Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 2Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 3Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 4Health News:HLM Venture Partners Leads Series B Financing of CaseNET, Inc. 2
... anyone using the Farnsworth D15, L'Anthony desaturated test ... patients cannot avoid touching the color disks with ... Further, the disks are very easy to loose.,We ... in order to solve these problems. We have ...
... Farnsworth Dichotomous testing sets are designed ... The Farnsworth D15 test is used to ... Normal. The L'Anthony Desaturated test is much ... mild deficiency from Normal. Both of ...
... The NOW Strep A test is as easy ... minutes to results. Increase patient satisfaction with rapid ... can treat your patient immediately with the appropriate ... , ,Intended Use: ,The NOW® Strep A Test ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Medicine Products: